Evidence map›Paper›PMID 34872449›Full record

ArticleBioengineered2021

Angiotensin (ang) 1-7 inhibits ang II-induced atrial fibrosis through regulating the interaction of proto-oncogene tyrosine-protein kinase Src (c-Src) and Src homology region 2 domain-containing phosphatase-1 (SHP-1)).

Li Lu, Li Cao, Yihao Liu, Yunlin Chen, Jinqi Fan, Yuehui Yin

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Li LuDepartment of Critical Care Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Li CaoDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yihao LiuDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yunlin ChenDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jinqi FanDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yuehui YinDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CNDalian Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To verify whether Ang-(1-7) produces an antagonistic effect on Ang II-mediated atrial remodeling. Ang II-induced HL-1 cell model and a rat model of Ang II-induced atrial remodeling were constructed and intervened with Ang II Ang-(1-7), AngII +Ang-(1-7), Ang II+ c-Src specific inhibitor (SU6656), and Ang II + Ang-(1-7) + SSG (SHP-1/2 specific inhibitor, stibogluconate), respectively. The systolic blood pressure of the rat caudal artery was detected. And trial fibrosis was detected by Picrosirius red staining and Masson's trichrome staining. Expressions of transforming growth factor-β (TGF-β), tissue inhibitor of metalloproteinases 1 (TIMP1), Matrix metalloproteinase 2 (MMP-2), connective tissue growth factor (CTGF), galectin-3, α-smooth muscle actin (α-SMA), and collagen I/III were subjected to qPCR and western blot. Furthermore, SHP-1 binding to c-Src was verified by co-immunoprecipitation (Co-IP). Results showed that the expressions of TGF-β, TIMP1, MMP-2, CTGF, α-SMA, galectin-3, and collagen I were increased markedly in the Ang II intervention group, and the expressions of p-ERK1/2, p-Akt, and p-p38MAPK were also increased dramatically. Ang-(1-7) or SU6656 addition could inhibit the action of Ang II factor, thereby minimizing the expressions of the previously described genes and proteins. Simultaneously, SSG supplement reversed the antagonistic effect of Ang-(1-7) on Ang II, and the latter elevated the blood pressure and induced atrial fibrosis in rats. Ang-(1-7) could reverse the changes related to Ang II-induced atrial fibrosis in rats. In conclusion, Ang-(1-7) antagonized Ang II-induced atrial remodeling by regulating SHP-1 and c-Src, thereby affecting the MAPKs/Akt signaling pathway.

Indexed as

Angiotensin IAngiotensin IIAnimalsFibrosisMatrix Metalloproteinase 2p38 Mitogen-Activated Protein KinasesPeptide FragmentsProtein Tyrosine Phosphatase, Non-Receptor Type 6Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-fynRatsRats, Sprague-DawleySignal Transductionsrc Homology DomainsTransforming Growth Factor betaAngiotensin Iangiotensin I (1-7)Angiotensin IIMatrix Metalloproteinase 2p38 Mitogen-Activated Protein KinasesPeptide FragmentsProtein Tyrosine Phosphatase, Non-Receptor Type 6Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-fynPtpn6 protein, ratTransforming Growth Factor betaAng-(1-7)ang iiatrial fibrosiscollagenc-srcmapksshp-1

Identifiers

PMID34872449
PMCPMC8809921
OpenAlexW4200141926

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.